Med Chem Res
line (OE33) by inducing apoptosis and cell cycle arrest. Carci-
nogenesis 25:1945–1952
Crofford L, Wilder R, Ristimaki A, Sano H, Remmers E, Epps H, Hla
T (1994) Cyclooxygenase-1 and -2 expression in rheumatoid
synovial tissues. Effects of interleukin-1 beta, phorbol ester, and
corticosteroids. J Clin Invest 93:1095–1101
DeWitt DL (1999) Cox-2-selective inhibitors: the new super aspirins.
Mol Pharm 55:625–631
Flower RJ (2003) The development of COX2 inhibitors. Nat Rev Drug
Discov 2:179–191
O’Leary KA, de Pascual-Teresa S, Needs PW, Bao YP, O’Brien NM,
Williamson G (2004) Effect of flavonoids and vitamin E on
cyclooxygenase-2 (COX-2) transcription. Mutat Res 551:
245–254
Phosrithong N, Samee W, Nunthanavanit P, Ungwitayatorn J (2012)
In Vitro antioxidant activity study of novel chromone derivatives.
Chem Biol Drug Des 79:981–989
Simmons DL, Botting RM, Hla T (2004) Cyclooxygenase Isozymes:
the biology of prostaglandin synthesis and inhibition. Pharmacol
Rev 56:387–437
Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P (1990) The
induction and suppression of prostaglandin H2 synthase
(cyclooxygenase) in human monocytes. J Biol Chem 265:
16737–16740
Suh Y, Afaq F, Johnson JJ, Mukhtar H (2009) A plant flavonoid fisetin
induces apoptosis in colon cancer cells by inhibition of COX2
and Wnt/EGFR/NF-kB-signaling pathways. Carcinogenesis
30:300–307
Gacche RN, Meshram RJ, Shegokar HD, Gond DS, Kamble SS,
Dhabadge VN, Utage BG, Patil KK, More RA (2015) Flavonoids
as a scaffold for development of novel anti-angiogenic agents: an
experimental and computational enquiry. Arch Biochem Biophys
577:35–48
Gierse JK, McDonald JJ, Hauser SD, Rangwala SH, Koboldt CM,
Seibert K (1996) A single amino acid difference between
cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selec-
Uddin MJ, Rao PNP, Rahim MA, McDonald R, Knaus EE (2004) A
new class of acyclic 2-alkyl-1,2-diaryl (E)-olefins as selective
cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med Chem Lett
14:4911–4914
Uddin MJ, Rao PNP, McDonald R, Knaus EE (2005) Design and
synthesis of (E)-1,1,2-triarylethenes: novel inhibitors of the
cyclooxygenase- 2 (COX-2) isozyme. Bioorg Med Chem Lett
15:439–442
tivity of COX-2 specific inhibitors.
15810–15814
Guo Q, Wang LH, Ruan KH, Kulmacz RJ (1996) Role of Val509 in
time-dependent inhibition of human prostaglandin H synthase-2
cyclooxygenase activity by isoform-selective agents. J Biol Chem
271:19134–19139
J
Biol Chem 271:
Ungwitayatorn J, Wiwat C, Samee W, Nunthanavanit P, Phosrithong
N (2011) Synthesis, in vitro evaluation, and docking studies of
novel chromone derivatives as HIV-1 protease inhibitor. J Mol
Struct 1001:152–161
Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenase 1 and 2.
Annu Rev Pharmacol Toxicol 38:97–120
Habeeb G, Rao PNP, Knaus EE (2001) Design and synthesis of 4,5-
diphenyl-4-isoxazolines: novel inhibitors of cyclooxygenase-2
with analgesic and antiinflammatory activity. J Med Chem
44:2921–2927
Havsteen B (1983) Flavonoids, a class of natural products of high
pharmacological potency. Biochem Pharmacol 32:1141–1148
Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA,
Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K,
Isakson PC, Stallings WC (1996) Structural basis for selective
inhibition of cyclooxygenase-2 by anti-inflammatory agents.
Nature 384:644–648
Lerdsirisuk P, Maicheen C, Ungwitayatorn J (2014) Antimalarial
activity of HIV-1 protease inhibitor in chromone series. Bioorg
Chem 57:142–147
Lin S-J, Tsai W-J, Chiou W-F, Yang T-H, Yang L-M (2008) Selective
COX-2 inhibitors. Part 2: synthesis and biological evaluation of
Wang JL, Carter J, Kiefer JR, Kurumbail RG, Pawlitz JL, Brown D,
Hartmann SJ, Graneto MJ, Seibert K, Talley JJ (2010) The novel
benzopyran class of selective cyclooxygenase-2 inhibitors-part I:
the first clinical candidate. Bioorg Med Chem Lett 20:7155–7158
Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL
(1991) Expression of a mitogen-responsive gene encoding pros-
taglandin synthase is regulated by mRNA splicing. Proc Natl
Acad Sci USA 88:2692–2696
Yucel T, Ahola H, Carlsted J, Modeer T (1999) Involvement of tyr-
osine kinases on cyclooxygenase expression and prostaglandin
E2 production in human gingival fibroblasts stimulated with
interleukin-1 beta and epidermal growth factor. Biochem Biophys
Res Commun 257:528–532
Zarghi A, Arfaee S, Rao PNP, Knaus EE (2006) Design, synthesis and
biological evaluation of 1,3-diarylprop-2-en-1-ones: a novel class
of cyclooxygenase-2 inhibitors. Bioorg Med Chem 14:2600–2605
Zarghi A, Rao PNP, Knaus EE (2007) Design and synthesis of new
rofecoxib analogs as selective cyclooxygenase-2 (COX-2) inhi-
bitors: replacement of the methanesulfonyl pharmacophore by an
4-benzylideneamino-
and
4-phenyliminomethyl-
benzenesulfonamides. Bioorg Med Chem 16:2697–2706
Lu X, Zhang H, Li X, Chen G, Li Q-S, Luo Y, Ruan B-F, Chen X-W,
Zhu H-L (2011) Design, synthesis and biological evaluation of
pyridine acyl sulfonamide derivatives as novel COX-2 inhibitors.
Bioorg Med Chem 19:6827–6832
Luong C, Miler A, Barnett J, Chow J, Ramesha C, Browner MF
(1996) Flexibility of the NSAID binding site in the structure of
human cyclooxygenase-2. Nat Struct Bio 3:927–933
N-acetylsulfonamido bioisostere.
J Pharm Pharmaceut Sci
10:159–167
Zarghi A, Kakhgi S, Hadipoor A, Daraee B, Dadrass OG, Hedayati M
(2008) Design and synthesis of 1,3-diarylurea derivatives as
selective cyclooxygenase (COX-2) inhibitors. Bioorg Med Chem
Lett 18:1336–1339